Glycopeptides are no more effective than β-lactam agents for prevention of surgical site infection after cardiac surgery: A meta-analysis

Clinical Infectious Diseases

Volumn 38, Issue 10, 2004, Pages 1357-1363

  Bolon, Maureen K ^a   Morlote, Monica ^c   Weber, Stephen G ^b   Koplan, Bruce ^d   Carmeli, Yehuda ^c   Wright, Sharon B ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; GLYCOPEPTIDE; METICILLIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; GRAM POSITIVE BACTERIUM; HEART SURGERY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SURGICAL INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BETA-LACTAMS; CLINICAL TRIALS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SURGICAL WOUND INFECTION; THORACIC SURGERY;

EID: 2442710122     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383318     Document Type: Article

References (45)

1. Ferraz EM, Bacelar TS, Aguiar JL, Ferraz AA, Pagnossin G, Batista JE. Wound infection rates in clean surgery: a potentially misleading risk classification. Infect Control Hosp Epidemiol 1992; 13:457-62.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002; 30:458-75.
3. Milano CA, Kesler K, Archibald N, Sexton DJ, Jones RH. Mediastinitis after coronary artery bypass graft surgery: risk factors and long-term survival. Circulation 1995; 92:2245-51.
4. Kappstein I, Schulgen G, Fraedrich G, Schlosser V, Schumacher M, Daschner FD. Added hospital stay due to wound infections following cardiac surgery. Thorac Cardiovasc Surg 1992; 40:148-51.
5. Asensio A, Torres J. Quantifying excess length of postoperative stay attributable to infections: a comparison of methods. J Clin Epidemiol 1999; 52:1249-56.
6. Hollenbeak CS, Murphy D, Dunagan WC, Fraser VJ. Nonrandom selection and the attributable cost of surgical-site infections. Infect Control Hosp Epidemiol 2002; 23:177-82.
7. Jenney AW, Harrington GA, Russo PL, Spelman DW. Cost of surgical site infections following coronary artery bypass surgery. ANZ J Surg 2001; 71:662-4.
8. Goodman JS, Schaffner W, Collins HA, Battersby EJ, Koenig MG. Infection after cardiovascular surgery: clinical study including examination of antimicrobial prophylaxis. N Engl J Med 1968; 278:117-23.
9. Fekety FR Jr, Cluff LE, Sabiston DC Jr, Seidl LG, Smith JW, Thoburn R. A study of antibiotic prophylaxis in cardiac surgery. J Thorac Cardiovasc Surg 1969; 57:757-63.
10. Fong IW, Baker CB, McKee DC. The value of prophylactic antibiotics in aorat-coronary bypass operations: a double-blind randomized trial. J Thorac Cardiovasc Surg 1979; 78:908-13.
11. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations: meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992; 104:590-9.
12. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther 2001; 43:92-7.
13. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29:404-21.
14. Olsen MA, Lock-Buckley P, Hopkins D, Polish LB, Sundt TM, Fraser VJ. The risk factors for deep and superficial chest surgical-site infections after coronary artery bypass graft surgery are different. J Thorac Cardiovasc Surg 2002; 124:136-45.
15. Borger MA, Rao V, Weisel RD, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998; 65:1050-6.
16. Grossi EA, Culliford AT, Krieger KH, et al. A survey of 77 major infectious complications of median sternotomy: a review of 7,949 consecutive operative procedures. Ann Thorac Surg 1985; 40:214-23.
17. Munoz P, Menasalvas A, Bernaldo de Quiros JC, Desco M, Vallejo JL, Bouza E. Postsurgical mediastinitis: a case-control study. Clin Infect Dis 1997; 25:1060-4.
18. Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg 2001; 20:1168-75.
19. Wang FD, Chang CH. Risk factors of deep sternal wound infections in coronary artery bypass graft surgery. J Cardiovasc Surg (Torino) 2000; 41:709-13.
20. L'Ecuyer PB, Murphy D, Little JR, Fraser VJ. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis 1996; 22:424-9.
21. Mossad SB, Serkey JM, Longworth DL, Cosgrove DM 3rd, Gordon SM. Coagulase-negative staphylococcal sternal wound infections after open heart operations. Ann Thorac Surg 1997; 63:395-401.
22. Zanetti G, Goldie SJ, Platt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 2001; 7:820-7.
23. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999; 159:2461-8.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin-Trials 1986; 7:177-88.
25. Bucknell SJ, Mohajeri M, Low J, McDonald M, Hill DG. Single-versus multiple-dose antibiotics prophylaxis for cardiac surgery. Aust N Z J Surg 2000; 70:409-11.
26. Niederhauser U, Vogt M, Vogt P, Genoni M, Kunzli A, Turina MI. Cardiac surgery in a high-risk group of patients: is prolonged post-operative antibiotic prophylaxis effective? J Thorac Cardiovasc Surg 1997; 114:162-8.
27. Romanelli VA, Howie MB, Myerowitz PD, et al. Intraoperative and postoperative effects of vancomycin administration in cardiac surgery patients: a prospective, double-blind, randomized trial. Crit Care Med 1993; 21:1124-31.
28. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002; 123:326-32.
29. Maki DG, Bohn MJ, Stolz SM, Kroncke GM, Acher CW, Myerowitz PD. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations: a double-blind randomized trial. J Thorac Cardiovasc Surg 1992; 104:1423-34.
30. Saginur R, Croteau D, Bergeron MG. Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients. The ESPRIT Group. J Thorac Cardiovasc Surg 2000; 120:1120-30.
31. Salminen US, Viljanen TU, Valtonen W, Ikonen TE, Sahlman AE, Harjula AL. Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. J Antimicrob Chemother 1999; 44:287-90.
32. Vuorisalo S, Pokela R, Syrjala H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998; 19:234-9.
33. Wilson AP, Treasure T, Gruneberg RN, Sturridge MF, Ross DN. Antibiotic prophylaxis in cardiac surgery: a prospective comparison of two dosage regimens of teicoplanin with a combination of flucloxacillin and tobramycin. J Antimicrob Chemother 1988; 21:213-23.
34. Wilson AP, Treasure T, Sturridge MF, et al. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Lancet 1986; 1(8476):311-3.
35. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 2000; 22:661-7.
36. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994; 38:396-9.
37. Martin C, Bourget P, Alaya M, et al. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997; 41:1150-5.
38. Wilson AP, Taylor B, Treasure T, et al. Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin. J Antimicrob Chemother 1988; 21:201-12.
39. Turnidge J, Grayson ML. Optimum treatment of staphylococcal infections. Drugs 1993; 45:353-66.
40. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26:61-4.
41. Apellaniz G, Valdes M, Perez R, et al. Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. J Chemother 1991; 3:91-7.
42. Gopal V, Bisno AL, Silverblatt FJ. Failure of vancomycin treatment in Staphylococcus aureus endocarditis: in vivo and in vitro observations. JAMA 1976; 236:1604-6.
43. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31.
44. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-7.
45. Spelman D, Harrington G, Russo P, Wesselingh S. Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol 2002; 23:402-4.